Our findings with Ova have clinical implications as these identified IM-insensitive hCSCs also exist in vivo as evidenced by the persistence of about 20% Bcr-Abl+ CD34+ and long-term culture-initiating cells in patients who achieved a complete cytogenetic response [27], low incidence of remission among IM-treated CML patients, and tumor recurrence when IM therapy is halted, often to blast crisis [28]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.